A detailed history of Bessemer Group Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Bessemer Group Inc holds 108,175 shares of BMY stock, worth $6.25 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
108,175
Previous 108,987 0.75%
Holding current value
$6.25 Million
Previous $4.53 Million 23.69%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$39.66 - $51.75 $32,203 - $42,021
-812 Reduced 0.75%
108,175 $5.6 Million
Q2 2024

Aug 13, 2024

SELL
$40.25 - $52.99 $2.02 Million - $2.65 Million
-50,079 Reduced 31.48%
108,987 $4.53 Million
Q1 2024

May 13, 2024

BUY
$47.98 - $54.4 $1.07 Million - $1.21 Million
22,286 Added 16.29%
159,066 $8.63 Million
Q4 2023

Feb 09, 2024

BUY
$48.48 - $57.85 $2.07 Million - $2.47 Million
42,674 Added 45.35%
136,780 $7.02 Million
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $132,568 - $148,231
-2,290 Reduced 2.38%
94,106 $5.46 Million
Q2 2023

Aug 10, 2023

BUY
$63.71 - $70.74 $901,432 - $1 Million
14,149 Added 17.2%
96,396 $6.16 Million
Q1 2023

May 10, 2023

SELL
$65.71 - $74.53 $511,289 - $579,917
-7,781 Reduced 8.64%
82,247 $5.7 Million
Q4 2022

Feb 13, 2023

SELL
$68.48 - $81.09 $326,307 - $386,393
-4,765 Reduced 5.03%
90,028 $6.48 Million
Q3 2022

Nov 09, 2022

BUY
$0.13 - $76.84 $875 - $517,363
6,733 Added 7.65%
94,793 $6.74 Million
Q2 2022

Aug 10, 2022

BUY
$72.62 - $79.98 $142,407 - $156,840
1,961 Added 2.28%
88,060 $6.78 Million
Q1 2022

May 12, 2022

BUY
$61.48 - $73.72 $794,690 - $952,904
12,926 Added 17.66%
86,099 $6.29 Million
Q4 2021

Jan 27, 2022

SELL
$53.63 - $62.52 $153 Million - $179 Million
-2,856,716 Reduced 97.5%
73,173 $4.56 Million
Q3 2021

Nov 12, 2021

BUY
$59.17 - $69.31 $1.48 Million - $1.73 Million
25,014 Added 0.86%
2,929,889 $173 Million
Q2 2021

Aug 06, 2021

BUY
$61.91 - $67.42 $6.61 Million - $7.2 Million
106,733 Added 3.81%
2,904,875 $194 Million
Q1 2021

May 13, 2021

BUY
$59.34 - $66.74 $9.42 Million - $10.6 Million
158,822 Added 6.02%
2,798,142 $177 Million
Q4 2020

Feb 09, 2021

BUY
$57.74 - $65.43 $19.9 Million - $22.5 Million
343,869 Added 14.98%
2,639,320 $164 Million
Q3 2020

Nov 12, 2020

BUY
$57.43 - $63.64 $126 Million - $139 Million
2,187,013 Added 2016.83%
2,295,451 $138 Million
Q2 2020

Aug 05, 2020

BUY
$54.82 - $64.09 $2.64 Million - $3.08 Million
48,101 Added 79.72%
108,438 $6.38 Million
Q1 2020

Apr 30, 2020

BUY
$46.4 - $67.43 $646,352 - $939,299
13,930 Added 30.02%
60,337 $3.36 Million
Q4 2019

Feb 04, 2020

BUY
$49.21 - $64.19 $315,682 - $411,778
6,415 Added 16.04%
46,407 $2.98 Million
Q3 2019

Nov 07, 2019

SELL
$42.77 - $50.71 $503,146 - $596,552
-11,764 Reduced 22.73%
39,992 $2.03 Million
Q2 2019

Jul 19, 2019

SELL
$44.62 - $49.34 $121,232 - $134,056
-2,717 Reduced 4.99%
51,756 $2.35 Million
Q1 2019

May 13, 2019

BUY
$45.12 - $53.8 $29,328 - $34,970
650 Added 1.21%
54,473 $2.6 Million
Q4 2018

Feb 12, 2019

BUY
$48.76 - $63.23 $261,792 - $339,481
5,369 Added 11.08%
53,823 $2.8 Million
Q3 2018

Nov 06, 2018

SELL
$55.19 - $62.25 $100,280 - $113,108
-1,817 Reduced 3.61%
48,454 $3.01 Million
Q2 2018

Jul 25, 2018

SELL
$50.53 - $62.98 $87.6 Million - $109 Million
-1,733,480 Reduced 97.18%
50,271 $2.78 Million
Q1 2018

May 10, 2018

BUY
$59.92 - $68.98 $759,486 - $874,321
12,675 Added 0.72%
1,783,751 $113 Million
Q4 2017

Jan 30, 2018

SELL
$59.94 - $65.35 $728,750 - $794,525
-12,158 Reduced 0.68%
1,771,076 $109 Million
Q3 2017

Nov 03, 2017

BUY
$55.23 - $63.74 $98.5 Million - $114 Million
1,783,234
1,783,234 $114 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Bessemer Group Inc Portfolio

Follow Bessemer Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bessemer Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bessemer Group Inc with notifications on news.